Loading...
Market
Future Structural Role of Proteologix in J&J by Mid-2025
4
Resolution / Starting Odds
Standalone Unit • 25%
Merged with J&J Immunology Division • 25%
Merged with J&J Research and Development • 25%
Dissolved with Assets Redistributed • 25%
Corporate announcements or strategic business reviews
Story
Johnson & Johnson to Acquire Proteologix for $850 Million to Boost Immunology Portfolio
May 16, 2024, 12:25 PM
On May 16, Johnson & Johnson announced that it will acquire privately held, stealthy start-up Proteologix for $850 million in cash, with the potential for additional milestone payments. The acquisition aims to bolster Johnson & Johnson's position in the treatment of atopic dermatitis and other immunologic disorders. Proteologix brings a pipeline of bispecific antibodies, including a phase 1-ready TSLP/IL13 bispecific and experimental treatments for asthma and atopic dermatitis. This acquisition, which includes dual-targeting antibody drugs, is part of Johnson & Johnson's strategy to expand its immunology portfolio and is the latest M&A deal involving molecules addressing TSLP.
View original story
Similar markets
Approved • 50%
Not Approved • 50%
Significant gain in market share • 33%
Moderate gain in market share • 34%
No significant change in market share • 33%
Yes • 50%
No • 50%
Successful • 33%
Partially successful • 34%
Unsuccessful • 33%
Significant increase in revenue • 25%
Moderate increase in revenue • 25%
No significant impact on revenue • 25%
Decrease in revenue • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
No further significant lawsuits • 33%
Few minor lawsuits • 33%
Significant new lawsuits • 34%
Fully integrated by mid-2025 • 25%
Fully integrated by end of 2025 • 25%
Integration delayed beyond 2025 • 25%
Integration halted or reversed • 25%
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Novartis • 25%
